Complications of Chimeric Antigen Receptor T-cell Therapy

Area of Science:

• Oncology
• Immunotherapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer treatment.
• While effective, CAR T-cell therapy is associated with a spectrum of potential adverse events.
• Understanding these toxicities is critical for safe clinical application.

Purpose of the Study:

• To provide a comprehensive overview of the potential side effects associated with CAR T-cell therapy.
• To highlight the importance of recognizing and managing both common and less frequent toxicities.
• To emphasize the need for a high index of suspicion in patients undergoing or having undergone CAR T-cell treatment.

Main Methods:

• Review of known complications associated with CAR T-cell therapy.
• Categorization of toxicities into well-known and other potential adverse events.
• Emphasis on clinical vigilance for patient monitoring.

Main Results:

• Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are recognized toxicities.
• Other potential complications include B- and T-cell aplasia/hypogammoglobulinemia, opportunistic infections, coagulopathies, graft versus host syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (HLH-like syndrome), and on-target off-tumor toxicities.
• These adverse events require careful monitoring and management.

Conclusions:

• CAR T-cell therapy necessitates vigilant monitoring for a range of potential side effects.
• Early recognition and prompt management of toxicities are essential for patient safety and treatment success.
• A high index of suspicion is paramount for clinicians managing patients receiving CAR T-cell therapy.